{
  "legislationId": "119_HR_8370",
  "lastUpdate": "2026-04-23T11:27:59.975Z",
  "history": [
    {
      "timestamp": "2026-04-23T11:27:59.975Z",
      "source_url": "https://www.congress.gov/119/bills/hr8370/BILLS-119hr8370ih.htm",
      "model": "gemini-flash-lite-latest",
      "prompt_sent": "\nROLE: Fact Checker.\nZADANIE: Porównaj SOURCE (oryginał) i SUMMARY (streszczenie przygotowane przez inne AI).\n\nTwoim celem jest wykrycie \"ZMYŚLONYCH KONKRETÓW\" (Fabricated Entities) w SUMMARY.\n\nSOURCE:\n[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 8370 Introduced in House (IH)] <DOC> 119th CONGRESS 2d Session H. R. 8370 To improve transparency and the availability of information regarding dietary supplements by amending the Federal Food, Drug, and Cosmetic Act to require manufacturers of dietary supplements to list dietary supplements with the Food and Drug Administration. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES April 20, 2026 Ms. Dexter introduced the following bill; which was referred to the Committee on Energy and Commerce _______________________________________________________________________ A BILL To improve transparency and the availability of information regarding dietary supplements by amending the Federal Food, Drug, and Cosmetic Act to require manufacturers of dietary supplements to list dietary supplements with the Food and Drug Administration. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Dietary Supplement Listing Act of 2026''. SEC. 2. REGULATION OF DIETARY SUPPLEMENTS. (a) In General.--Chapter IV of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 341 et seq.) is amended by inserting after section 403C of such Act (21 U.S.C. 343-3) the following: ``SEC. 403D. DIETARY SUPPLEMENT LISTING REQUIREMENT. ``(a) In General.--Beginning on the date specified in subsection (b)(4), each dietary supplement marketed in the United States shall be listed with the Secretary in accordance with this section. Each such listing shall include, with respect to the dietary supplement, the information specified in subsection (b)(1). ``(b) Requirements.-- ``(1) In general.--The manufacturer, packer, or distributor of a dietary supplement whose name (pursuant to section 403(e)(1)) appears on the label of a dietary supplement marketed in the United States (referred to in this section as the `responsible person'), or if the responsible person is a foreign entity, the United States agent of such person, shall submit to the Secretary in accordance with this section the following information for a dietary supplement that is marketed in the United States: ``(A) Any name of the dietary supplement and the statement of identity, including brand name and specified flavors, if applicable. ``(B) The name and address of the responsible person and the name and email address of the owner, operator, or agent in charge of the responsible person. ``(C) The name, domestic address, and email address for the United States agent, if the responsible person is a foreign entity. ``(D) The business name and place of business the responsible person provided on the label pursuant to section 403(e)(1). ``(E) An electronic copy of the label for the dietary supplement. ``(F) A list of all ingredients in each such dietary supplement required under sections 101.4 and 101.36, title 21, Code of Federal Regulations (or any successor regulations), to appear on the label of a dietary supplement, including-- ``(i) where applicable, ingredients in a proprietary blend as described in section 101.36(c) of title 21, Code of Federal Regulations (or any successor regulations); ``(ii) the amount per serving of each listed dietary ingredient; ``(iii) if required by section 101.36 of title 21, Code of Federal Regulations (or any successor regulations), the percent of the daily value of each listed dietary ingredient; and ``(iv) the amount per serving of dietary ingredients within a proprietary blend (which shall remain confidential and not subject to public disclosure). ``(G) The number of servings per container for each container size. ``(H) The directions for use. ``(I) Warnings, notice, and safe handling statements, as required by section 101.17 of title 21, Code of Federal Regulations (or any successor regulations). ``(J) Allergen statements for major food allergens (pursuant to sections 403(w) and 403(x)). ``(K) The form of the dietary supplement (such as tablets, capsules, powders, liquids, softgels, and gummies). ``(L) Any claim that appears on the label or package insert that-- ``(i) characterizes the relationship of any ingredient to a disease or a health-related condition and is described in section 403(r)(1)(B); or ``(ii) is subject to notification under section 403(r)(6), provided that no additional listing or change to listing information is required under this paragraph for any minor variation or modification to a claim for which notification under section 403(r)(6) is not required. ``(M) The dietary supplement product listing number for the dietary supplement provided by the Secretary in accordance with subsection (c). ``(2) Format; notification of receipt.-- ``(A) Format.--The Secretary may require that a listing submitted under paragraph (1) be submitted in an electronic format. ``(B) Notification of receipt.-- ``(i) In general.--Upon receipt of a listing under paragraph (1), the Secretary shall promptly notify the responsible person of-- ``(I) the receipt of a complete listing; or ``(II) the receipt of a listing that is not complete, together with a statement describing the reasons why the listing is not complete. ``(ii) Complete receipts described.--A listing under paragraph (1) is deemed complete once all fields of required information have been completed by the responsible person who represents that the product will be marketed in the United States as a dietary supplement. ``(3) Listing content.--A single listing submission for a dietary supplement under paragraph (1) may include multiple dietary supplements with identical formulations and forms, or formulations of the same form, that differ only with respect to color, excipients, or flavorings, whether offered in a single package size or in multiple package sizes. ``(4) Timing.-- ``(A) In general.-- ``(i) Dietary supplements on the market.-- In the case of a dietary supplement that is being offered in interstate commerce on or before January 1, 2027, a listing for each such dietary supplement introduced or delivered for introduction into interstate commerce shall be submitted by the responsible person to the Secretary under this subsection not later than 18 months after the date of enactment of the Dietary Supplement Listing Act of 2026. Beginning on the date that is 2 years after such date of enactment, the label for each such dietary supplement shall include the dietary supplement product listing number provided by the Secretary in accordance with subsection (c). ``(ii) New dietary supplements.--In the case of a dietary supplement that is not being offered in interstate commerce on or before January 1, 2027, a listing for each such dietary supplement introduced or delivered for introduction into interstate commerce that has not been included in any listing previously submitted by the responsible person to the Secretary under this subsection shall be submitted to the Secretary at the time of introduction into interstate commerce. The label for each such dietary supplement shall include, at the time of introduction or delivery for introduction into interstate commerce, the dietary supplement product listing number provided by the Secretary in accordance with subsection (c). ``(B) Discontinued dietary supplements.--The responsible person shall notify the Secretary not later than 1 year after the date the responsible person discontinues the introduction into interstate commerce of a dietary supplement required to be listed with the Secretary under paragraph (1). ``(C) Changes to existing listings.--The responsible person shall submit to the Secretary any change or modification to listing information submitted under paragraph (1) included on the label of a dietary supplement at the time the dietary supplement with the change or modification is first introduced into interstate commerce. ``(5) Additional information.--The responsible person shall provide, upon request from the Secretary, not later than 5 calendar days after such request-- ``(A) the full business name and physical and mailing address of all locations at which the responsible person manufactures, packages, labels, or holds the dietary supplement; and ``(B) the full business name and physical and mailing address from which the responsible person receives a dietary ingredient or combination of dietary ingredients that the responsible person uses in the manufacture of the dietary supplement or, if applicable, from which the responsible person receives the dietary supplement. ``(c) Product Listing Number and Dietary Supplement Electronic Database.-- ``(1) Dietary supplement product listing number.--The Secretary shall provide each dietary supplement listed in accordance with subsection (b)(1) a dietary supplement product listing number, which may apply to multiple dietary supplements with identical formulations, or formulations that differ only with respect to color, excipients, or flavorings, including dietary supplements offered in a single package size or in multiple package sizes. The Secretary shall provide a process for a responsible person to reserve dietary supplement listing numbers in advance of listing under subsection (b)(1). ``(2) Electronic database.--Not later than 2 years after the date of enactment of the Dietary Supplement Listing Act of 2026, the Secretary shall establish and maintain an electronic database that is publicly available and contains information submitted under subsection (b)(1) (except for the information submitted under subparagraphs (B), (C), and (F)(iv) of such subsection). The Secretary shall make such information maintained in the electronic database publicly searchable, including by dietary supplement product listing number, and by any field of information or combination of fields of information provided under subsection (b)(1) (except for the information submitted under subparagraphs (B), (C), and (F)(iv) of such subsection). ``(3) Confidential information.--In response to a request under section 552 of title 5, United States Code, information described in subparagraphs (B), (C), and (F)(iv) of subsection (b)(1) that is derived from a listing under this section, and information described in subparagraph (b)(5), shall be withheld under section 552(b)(3) of title 5, United States Code. ``(d) Rule of Construction.--Nothing in this section shall be construed-- ``(1) to limit the authority of the Secretary to inspect or copy records or to require the establishment and maintenance of records under any other provision of this Act; ``(2) to authorize the disclosure of information that is prohibited from disclosure under section 301(j) of this Act or section 1905 of title 18, United States Code, or that is subject to withholding under section 552(b)(4) of title 5, United States Code; ``(3) to authorize or permit the release in the public database, or to make subject to disclosure under section 552 of title 5, United States Code, information that discloses the identity or location of a specific registered person or facility not identified on the label, or the quantity of any individual ingredients in a proprietary blend; or ``(4) to grant the Secretary authority to require the approval of a dietary supplement prior to marketing. ``(e) Authorization of Appropriations.--There is authorized to be appropriated $7,872,984 for fiscal year 2026, and $6,615,000 for each of fiscal years 2027 through 2030, for purposes of conducting the activities under this section and hiring personnel required to carry out this section.''. (b) Misbranding.--Section 403 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 343) is amended by adding at the end the following: ``(z) If it is a dietary supplement for which a responsible person or the United States agent of such a person is required under section 403D to file a listing, file a change to an existing listing, or provide additional information to the Secretary, and such person or agent has failed to comply with any such requirements under section 403D with respect to such dietary supplement.''. <all>\n\nSUMMARY TO EVALUATE:\nTitle: Dietary Supplement Listing Act of 2026\nSummary: This act requires supplement manufacturers to register their products with the FDA to increase transparency. It creates a public database where citizens can easily check ingredients and safety warnings for the supplements they use.\nKey Points: Mandatory registration of all dietary supplements marketed in the United States., Creation of a searchable public electronic database for consumer use., Requirement for a unique product listing number to appear on all supplement labels., Public access to detailed ingredient lists, allergen statements, and safety warnings., Products not listed with the FDA will be considered misbranded and subject to removal.\n\nZASADY OCENY:\n1. Sprawdź wszystkie LICZBY, DATY i KWOTY w SUMMARY. Jeśli którejś brakuje w SOURCE -> is_valid: false.\n2. Sprawdź wszystkie NAZWISKA, ORGANIZACJE i MIEJSCA w SUMMARY. Jeśli którejś brakuje w SOURCE -> is_valid: false.\n3. Sprawdź wszystkie konkretne DZIAŁANIA PRAWNE . Jeśli tego mechanizmu nie ma w SOURCE -> is_valid: false.\n\nWAŻNE: Abstrakcyjne pojęcia (np. \"transparentność\", \"zaufanie\") są dozwolone jako wnioski.\n\nOUTPUT (JSON):\n{\n  \"is_valid\": true/false,\n  \"issue\": \"fabricated_entity\" / \"contradiction\" / \"none\"\n}\n\nWYMAGANIA FORMATOWANIA:\n1. Odpowiedz WYŁĄCZNIE surowym obiektem JSON.\n2. NIE używaj bloków kodu Markdown.\n3. NIE dodawaj żadnych wstępów ani wyjaśnień przed ani po JSONie.\n4. JSON musi być poprawny i gotowy do parsowania.\n\n",
      "ai_response_raw": "{\n  \"is_valid\": true,\n  \"issue\": \"none\"\n}"
    },
    {
      "timestamp": "2026-04-23T11:15:38.381Z",
      "source_url": "https://www.congress.gov/119/bills/hr8370/BILLS-119hr8370ih.htm",
      "model": "gemini-flash-latest",
      "prompt_sent": "\nJesteś ekspertem od prawa Stanów Zjednoczonych, który ma za zadanie analizować dokumenty ustaw, uchwał oraz innych dokumentów legislacyjnych, a następnie przygotowywać z nich informacje w przystępny sposób dla obywateli. Twoim celem jest przedstawienie informacji tak, aby obywatele mogli sami ocenić wpływ legislacji na ich życie, nawet bez posiadania specjalistycznej wiedzy legislacyjnej. Skup się na faktach i obiektywnych skutkach wprowadzanych zmian, unikając wartościowania i osobistych opinii. Wszelki żargon prawny jest zabroniony. Prezentuj informacje w jasny, zwięzły i angażujący sposób, tak aby były zrozumiałe dla osoby bez wykształcenia prawniczego. Unikaj długich, złożonych zdań. Zamiast pisać \"projekt ma na celu nowelizację kodeksu podatkowego...\", napisz \"Zmiany w podatkach: nowe ulgi i obowiązki dla...\". Kontynuuj swoją pracę, dopóki nie rozwiążesz swojego zadania. Jeśli nie masz pewności co do generowanej treści, przeanalizuj dokument ponownie – nie zgaduj. Rozplanuj dobrze swoje zadanie przed przystąpieniem do niego. W podsumowaniu i kluczowych punktach, jeśli to możliwe i uzasadnione, podkreśl, jakie konkretne korzyści lub skutki (pozytywne lub negatywne) wprowadza ustawa dla życia codziennego obywateli, ich praw i obowiązków, finansów osobistych, bezpieczeństwa i innych ważnych kwestii (np. kategorycznych zakazów i nakazów czy najważniejszych konkretnych alokacji finansowych i terytorialnych).\n\nTwoja odpowiedź MUSI być w formacie JSON - i zawierać następujące klucze.\nZanim zwrócisz odpowiedź, dokładnie zweryfikuj, czy cała struktura JSON jest w 100% poprawna, włącznie ze wszystkimi przecinkami, nawiasami klamrowymi, kwadratowymi oraz cudzysłowami. Błędny JSON jest nieakceptowalny i uniemożliwi przetworzenie Twojej pracy.\n\nPrzeanalizuj dokładnie poniższy tekst dokumentu prawnego. To jest treść, na podstawie której masz wygenerować podsumowanie i kluczowe punkty:\n--- POCZĄTEK DOKUMENTU ---\n[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 8370 Introduced in House (IH)] <DOC> 119th CONGRESS 2d Session H. R. 8370 To improve transparency and the availability of information regarding dietary supplements by amending the Federal Food, Drug, and Cosmetic Act to require manufacturers of dietary supplements to list dietary supplements with the Food and Drug Administration. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES April 20, 2026 Ms. Dexter introduced the following bill; which was referred to the Committee on Energy and Commerce _______________________________________________________________________ A BILL To improve transparency and the availability of information regarding dietary supplements by amending the Federal Food, Drug, and Cosmetic Act to require manufacturers of dietary supplements to list dietary supplements with the Food and Drug Administration. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Dietary Supplement Listing Act of 2026''. SEC. 2. REGULATION OF DIETARY SUPPLEMENTS. (a) In General.--Chapter IV of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 341 et seq.) is amended by inserting after section 403C of such Act (21 U.S.C. 343-3) the following: ``SEC. 403D. DIETARY SUPPLEMENT LISTING REQUIREMENT. ``(a) In General.--Beginning on the date specified in subsection (b)(4), each dietary supplement marketed in the United States shall be listed with the Secretary in accordance with this section. Each such listing shall include, with respect to the dietary supplement, the information specified in subsection (b)(1). ``(b) Requirements.-- ``(1) In general.--The manufacturer, packer, or distributor of a dietary supplement whose name (pursuant to section 403(e)(1)) appears on the label of a dietary supplement marketed in the United States (referred to in this section as the `responsible person'), or if the responsible person is a foreign entity, the United States agent of such person, shall submit to the Secretary in accordance with this section the following information for a dietary supplement that is marketed in the United States: ``(A) Any name of the dietary supplement and the statement of identity, including brand name and specified flavors, if applicable. ``(B) The name and address of the responsible person and the name and email address of the owner, operator, or agent in charge of the responsible person. ``(C) The name, domestic address, and email address for the United States agent, if the responsible person is a foreign entity. ``(D) The business name and place of business the responsible person provided on the label pursuant to section 403(e)(1). ``(E) An electronic copy of the label for the dietary supplement. ``(F) A list of all ingredients in each such dietary supplement required under sections 101.4 and 101.36, title 21, Code of Federal Regulations (or any successor regulations), to appear on the label of a dietary supplement, including-- ``(i) where applicable, ingredients in a proprietary blend as described in section 101.36(c) of title 21, Code of Federal Regulations (or any successor regulations); ``(ii) the amount per serving of each listed dietary ingredient; ``(iii) if required by section 101.36 of title 21, Code of Federal Regulations (or any successor regulations), the percent of the daily value of each listed dietary ingredient; and ``(iv) the amount per serving of dietary ingredients within a proprietary blend (which shall remain confidential and not subject to public disclosure). ``(G) The number of servings per container for each container size. ``(H) The directions for use. ``(I) Warnings, notice, and safe handling statements, as required by section 101.17 of title 21, Code of Federal Regulations (or any successor regulations). ``(J) Allergen statements for major food allergens (pursuant to sections 403(w) and 403(x)). ``(K) The form of the dietary supplement (such as tablets, capsules, powders, liquids, softgels, and gummies). ``(L) Any claim that appears on the label or package insert that-- ``(i) characterizes the relationship of any ingredient to a disease or a health-related condition and is described in section 403(r)(1)(B); or ``(ii) is subject to notification under section 403(r)(6), provided that no additional listing or change to listing information is required under this paragraph for any minor variation or modification to a claim for which notification under section 403(r)(6) is not required. ``(M) The dietary supplement product listing number for the dietary supplement provided by the Secretary in accordance with subsection (c). ``(2) Format; notification of receipt.-- ``(A) Format.--The Secretary may require that a listing submitted under paragraph (1) be submitted in an electronic format. ``(B) Notification of receipt.-- ``(i) In general.--Upon receipt of a listing under paragraph (1), the Secretary shall promptly notify the responsible person of-- ``(I) the receipt of a complete listing; or ``(II) the receipt of a listing that is not complete, together with a statement describing the reasons why the listing is not complete. ``(ii) Complete receipts described.--A listing under paragraph (1) is deemed complete once all fields of required information have been completed by the responsible person who represents that the product will be marketed in the United States as a dietary supplement. ``(3) Listing content.--A single listing submission for a dietary supplement under paragraph (1) may include multiple dietary supplements with identical formulations and forms, or formulations of the same form, that differ only with respect to color, excipients, or flavorings, whether offered in a single package size or in multiple package sizes. ``(4) Timing.-- ``(A) In general.-- ``(i) Dietary supplements on the market.-- In the case of a dietary supplement that is being offered in interstate commerce on or before January 1, 2027, a listing for each such dietary supplement introduced or delivered for introduction into interstate commerce shall be submitted by the responsible person to the Secretary under this subsection not later than 18 months after the date of enactment of the Dietary Supplement Listing Act of 2026. Beginning on the date that is 2 years after such date of enactment, the label for each such dietary supplement shall include the dietary supplement product listing number provided by the Secretary in accordance with subsection (c). ``(ii) New dietary supplements.--In the case of a dietary supplement that is not being offered in interstate commerce on or before January 1, 2027, a listing for each such dietary supplement introduced or delivered for introduction into interstate commerce that has not been included in any listing previously submitted by the responsible person to the Secretary under this subsection shall be submitted to the Secretary at the time of introduction into interstate commerce. The label for each such dietary supplement shall include, at the time of introduction or delivery for introduction into interstate commerce, the dietary supplement product listing number provided by the Secretary in accordance with subsection (c). ``(B) Discontinued dietary supplements.--The responsible person shall notify the Secretary not later than 1 year after the date the responsible person discontinues the introduction into interstate commerce of a dietary supplement required to be listed with the Secretary under paragraph (1). ``(C) Changes to existing listings.--The responsible person shall submit to the Secretary any change or modification to listing information submitted under paragraph (1) included on the label of a dietary supplement at the time the dietary supplement with the change or modification is first introduced into interstate commerce. ``(5) Additional information.--The responsible person shall provide, upon request from the Secretary, not later than 5 calendar days after such request-- ``(A) the full business name and physical and mailing address of all locations at which the responsible person manufactures, packages, labels, or holds the dietary supplement; and ``(B) the full business name and physical and mailing address from which the responsible person receives a dietary ingredient or combination of dietary ingredients that the responsible person uses in the manufacture of the dietary supplement or, if applicable, from which the responsible person receives the dietary supplement. ``(c) Product Listing Number and Dietary Supplement Electronic Database.-- ``(1) Dietary supplement product listing number.--The Secretary shall provide each dietary supplement listed in accordance with subsection (b)(1) a dietary supplement product listing number, which may apply to multiple dietary supplements with identical formulations, or formulations that differ only with respect to color, excipients, or flavorings, including dietary supplements offered in a single package size or in multiple package sizes. The Secretary shall provide a process for a responsible person to reserve dietary supplement listing numbers in advance of listing under subsection (b)(1). ``(2) Electronic database.--Not later than 2 years after the date of enactment of the Dietary Supplement Listing Act of 2026, the Secretary shall establish and maintain an electronic database that is publicly available and contains information submitted under subsection (b)(1) (except for the information submitted under subparagraphs (B), (C), and (F)(iv) of such subsection). The Secretary shall make such information maintained in the electronic database publicly searchable, including by dietary supplement product listing number, and by any field of information or combination of fields of information provided under subsection (b)(1) (except for the information submitted under subparagraphs (B), (C), and (F)(iv) of such subsection). ``(3) Confidential information.--In response to a request under section 552 of title 5, United States Code, information described in subparagraphs (B), (C), and (F)(iv) of subsection (b)(1) that is derived from a listing under this section, and information described in subparagraph (b)(5), shall be withheld under section 552(b)(3) of title 5, United States Code. ``(d) Rule of Construction.--Nothing in this section shall be construed-- ``(1) to limit the authority of the Secretary to inspect or copy records or to require the establishment and maintenance of records under any other provision of this Act; ``(2) to authorize the disclosure of information that is prohibited from disclosure under section 301(j) of this Act or section 1905 of title 18, United States Code, or that is subject to withholding under section 552(b)(4) of title 5, United States Code; ``(3) to authorize or permit the release in the public database, or to make subject to disclosure under section 552 of title 5, United States Code, information that discloses the identity or location of a specific registered person or facility not identified on the label, or the quantity of any individual ingredients in a proprietary blend; or ``(4) to grant the Secretary authority to require the approval of a dietary supplement prior to marketing. ``(e) Authorization of Appropriations.--There is authorized to be appropriated $7,872,984 for fiscal year 2026, and $6,615,000 for each of fiscal years 2027 through 2030, for purposes of conducting the activities under this section and hiring personnel required to carry out this section.''. (b) Misbranding.--Section 403 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 343) is amended by adding at the end the following: ``(z) If it is a dietary supplement for which a responsible person or the United States agent of such a person is required under section 403D to file a listing, file a change to an existing listing, or provide additional information to the Secretary, and such person or agent has failed to comply with any such requirements under section 403D with respect to such dietary supplement.''. <all>\n--- KONIEC DOKUMENTU ---\n\nPAMIĘTAJ: Twoja odpowiedź MUSI być wyłącznie poprawnym obiektem JSON. Nie dodawaj żadnych dodatkowych znaków, komentarzy ani tekstu przed znacznikiem '{' ani po znaczniku '}'. Cała odpowiedź musi być parsowalna jako JSON.\nNa podstawie POWYŻSZEGO dokumentu, wypełnij poniższą strukturę JSON:\nOto struktura JSON, której oczekuję (wypełnij ją treścią):\n{\n  \"pl_ai_title\": \"Nowy, krótki tytuł dla aktu prawnego po polsku, oddający sedno wprowadzanych zmian (np. maksymalnie 10-12 słów).\",\n  \"pl_summary\": \"2-3 zdania zwięzłego podsumowania treści aktu prawnego po polsku, napisane z perspektywy wpływu na życie codzienne obywateli.\",\n  \"pl_key_points\": [\n    \"Pierwszy krótki punkt po polsku dotyczący najważniejszych wprowadzanych rozwiązań lub zmian.\",\n    \"Drugi krótki punkt po polsku...\"\n  ],\n  \"eng_ai_title\": \"A new, short title for the legal act in English, capturing the essence of the changes (e.g., max 10-12 words).\",\n  \"eng_summary\": \"2-3 sentences summarizing the legal act in English, from the perspective of its impact on citizens' daily lives.\",\n  \"eng_key_points\": [\n    \"First short bullet point in English regarding the most important solutions or changes being introduced.\",\n    \"Second short bullet point in English...\"\n  ],\n  \"de_ai_title\": \"Ein neuer, kurzer Titel für das Rechtsdokument auf Deutsch, der den Kern der Änderungen erfasst (z.B. max. 10-12 Wörter).\",\n  \"de_summary\": \"2-3 Sätze Zusammenfassung des Rechtsdokuments auf Deutsch, aus der Perspektive seiner Auswirkungen auf das tägliche Leben der Bürger.\",\n  \"de_key_points\": [\n    \"Erster kurzer Stichpunkt auf Deutsch zu den wichtigsten eingeführten Lösungen oder Änderungen.\",\n    \"Zweiter kurzer Stichpunkt auf Deutsch...\"\n  ],\n  \"fr_ai_title\": \"Un nouveau titre court pour l'acte juridique en français, saisissant l'essence des changements (par exemple, 10-12 mots maximum).\",\n  \"fr_summary\": \"Résumé de 2-3 phrases de l'acte juridique en français, du point de vue de son impact sur la vie quotidienne des citoyens.\",\n  \"fr_key_points\": [\n    \"Premier court point en français concernant les solutions ou changements les plus importants introduits.\",\n    \"Deuxième court point en français...\"\n  ],\n  \"es_ai_title\": \"Un nuevo título breve para el acto jurídico en español, que recoja la esencia de los cambios (por ejemplo, máximo 10-12 palabras).\",\n  \"es_summary\": \"Resumen de 2-3 frases del acto jurídico en español, desde la perspectiva de su impacto en la vida cotidiana de los ciudadanos.\",\n  \"es_key_points\": [\n    \"Primer punto breve en español sobre las soluciones o cambios más importantes que se introducen.\",\n    \"Segundo punto breve en español...\"\n  ],\n  \"it_ai_title\": \"Un nuovo titolo breve per l'atto giuridico in italiano, che colga l'essenza delle modifiche (ad es. massimo 10-12 parole).\",\n  \"it_summary\": \"Riepilogo di 2-3 frasi dell'atto giuridico in italiano, dal punto di vista del suo impatto sulla vita quotidiana dei cittadini.\",\n  \"it_key_points\": [\n    \"Primo breve punto in italiano riguardante le soluzioni o le modifiche più importanti introdotte.\",\n    \"Secondo breve punto in italiano...\"\n  ],\n  \"nl_ai_title\": \"Een nieuwe, korte titel voor de rechtshandeling in het Nederlands, die de essentie van de wijzigingen weergeeft (bijv. max. 10-12 woorden).\",\n  \"nl_summary\": \"Samenvatting van 2-3 zinnen van de rechtshandeling in het Nederlands, vanuit het perspectief van de impact op het dagelijks leven van burgers.\",\n  \"nl_key_points\": [\n    \"Eerste korte punt in het Nederlands betreffende de belangrijkste geïntroduceerde oplossingen of wijzigingen.\",\n    \"Tweede korte punt in het Nederlands...\"\n  ],\n  \"pt_ai_title\": \"Um novo título curto para o ato jurídico em português, capturando a essência das mudanças (por exemplo, máx. 10-12 palavras).\",\n  \"pt_summary\": \"Resumo de 2-3 frases do ato jurídico em português, na perspetiva do seu impacto na vida quotidiana dos cidadãos.\",\n  \"pt_key_points\": [\n    \"Primeiro ponto curto em português sobre as soluções ou alterações mais importantes introduzidas.\",\n    \"Segundo ponto curto em português...\"\n  ],\n  \"category\": [\"Categorize the document into one category by default, based on the field it primarily concerns. Choose up to 3 if the document also touches upon SIGNIFICANT issues from other categories. You MUST select categories ONLY from the following list: Health, Education, Family, Taxes, Labor, Security, Environment, Courts and Law, Transport, Benefits, Real Estate, Media and Culture, Local Government, Migration, Agriculture, Public Investments, Informatization, Economy. If the document does not definitively fit any of these, you MUST use \"Other\". If you use \"Other\", it should be the ONLY category selected. Do NOT invent new categories. The response must be an array of strings, e.g., [\"Taxes\", \"Family\"].\"]\n}\n\n",
      "ai_response_raw": "{\n  \"pl_ai_title\": \"Ustawa o rejestracji suplementów diety z 2026 roku\",\n  \"pl_summary\": \"Nowe przepisy nakładają na producentów obowiązek rejestrowania suplementów diety w specjalnej bazie danych FDA. Dzięki temu obywatele zyskają łatwy dostęp do sprawdzonych informacji o składzie, alergenach i bezpieczeństwie produktów, które kupują.\",\n  \"pl_key_points\": [\n    \"Wprowadzenie obowiązkowej rejestracji wszystkich suplementów diety sprzedawanych w USA.\",\n    \"Utworzenie publicznej, bezpłatnej bazy danych online dla konsumentów.\",\n    \"Wymóg umieszczania specjalnego numeru identyfikacyjnego na etykiecie każdego produktu.\",\n    \"Udostępnienie pełnej listy składników, ostrzeżeń i informacji o alergenach w internecie.\",\n    \"Surowe kary dla firm, które nie zarejestrują swoich produktów w wyznaczonym terminie.\"\n  ],\n  \"eng_ai_title\": \"Dietary Supplement Listing Act of 2026\",\n  \"eng_summary\": \"This act requires supplement manufacturers to register their products with the FDA to increase transparency. It creates a public database where citizens can easily check ingredients and safety warnings for the supplements they use.\",\n  \"eng_key_points\": [\n    \"Mandatory registration of all dietary supplements marketed in the United States.\",\n    \"Creation of a searchable public electronic database for consumer use.\",\n    \"Requirement for a unique product listing number to appear on all supplement labels.\",\n    \"Public access to detailed ingredient lists, allergen statements, and safety warnings.\",\n    \"Products not listed with the FDA will be considered misbranded and subject to removal.\"\n  ],\n  \"de_ai_title\": \"Gesetz zur Registrierung von Nahrungsergänzungsmitteln 2026\",\n  \"de_summary\": \"Dieses Gesetz verpflichtet Hersteller, Nahrungsergänzungsmittel bei der FDA zu registrieren, um die Transparenz zu erhöhen. Bürger erhalten Zugang zu einer öffentlichen Datenbank, um Inhaltsstoffe und Sicherheitshinweise ihrer Produkte leichter zu überprüfen.\",\n  \"de_key_points\": [\n    \"Verpflichtende Meldung aller Nahrungsergänzungsmittel bei der US-Behörde FDA.\",\n    \"Einrichtung einer öffentlich durchsuchbaren Datenbank für alle Verbraucher.\",\n    \"Neue Identifikationsnummern müssen auf den Etiketten der Produkte stehen.\",\n    \"Transparenz bei Inhaltsstoffen, Allergenen und wichtigen Warnhinweisen online.\",\n    \"Nicht registrierte Produkte dürfen künftig nicht mehr verkauft werden.\"\n  ],\n  \"fr_ai_title\": \"Loi de 2026 sur le référencement des compléments alimentaires\",\n  \"fr_summary\": \"Cette loi oblige les fabricants à enregistrer leurs compléments alimentaires auprès de la FDA pour plus de transparence. Elle crée une base de données publique permettant aux citoyens de vérifier facilement la composition et les avertissements de sécurité.\",\n  \"fr_key_points\": [\n    \"Enregistrement obligatoire de tous les compléments alimentaires auprès de la FDA.\",\n    \"Création d'une base de données publique consultable gratuitement par les consommateurs.\",\n    \"Obligation d'afficher un numéro d'identification unique sur chaque étiquette de produit.\",\n    \"Accès en ligne aux listes d'ingrédients, aux allergènes et aux consignes de sécurité.\",\n    \"Interdiction de commercialiser des produits non enregistrés dans les délais prévus.\"\n  ],\n  \"es_ai_title\": \"Ley de Registro de Suplementos Dietéticos de 2026\",\n  \"es_summary\": \"Esta ley exige que los fabricantes registren sus suplementos ante la FDA para mejorar la transparencia. Se creará una base de datos pública donde los ciudadanos podrán consultar ingredientes y advertencias de seguridad de forma sencilla.\",\n  \"es_key_points\": [\n    \"Registro obligatorio de todos los suplementos dietéticos ante la FDA.\",\n    \"Creación de una base de datos electrónica pública para el uso de los consumidores.\",\n    \"Requisito de incluir un número de registro oficial en las etiquetas de los productos.\",\n    \"Información detallada sobre ingredientes, alérgenos y advertencias disponible en línea.\",\n    \"Los productos que no cumplan con el registro serán considerados ilegales para la venta.\"\n  ],\n  \"it_ai_title\": \"Legge sulla registrazione degli integratori alimentari del 2026\",\n  \"it_summary\": \"Questa legge impone ai produttori di registrare gli integratori alimentari presso la FDA per aumentare la trasparenza. Viene istituito un database pubblico per consentire ai cittadini di verificare ingredienti e avvertenze di sicurezza.\",\n  \"it_key_points\": [\n    \"Registrazione obbligatoria di tutti gli integratori alimentari presso la FDA.\",\n    \"Creazione di un database pubblico online consultabile da tutti i cittadini.\",\n    \"Obbligo di riportare un numero identificativo univoco sulle etichette dei prodotti.\",\n    \"Accesso facilitato a informazioni su ingredienti, allergeni e modalità d'uso sicuro.\",\n    \"Sanzioni e divieto di vendita per i prodotti non regolarmente registrati.\"\n  ],\n  \"nl_ai_title\": \"Wet op de registratie van voedingssupplementen van 2026\",\n  \"nl_summary\": \"Deze wet verplicht fabrikanten om voedingssupplementen te registreren bij de FDA. Er komt een openbare database waarin burgers eenvoudig de ingrediënten en veiligheidswaarschuwingen van hun producten kunnen opzoeken.\",\n  \"nl_key_points\": [\n    \"Verplichte registratie van alle voedingssupplementen bij de Amerikaanse FDA.\",\n    \"Oprichting van een openbaar doorzoekbare database voor alle consumenten.\",\n    \"Unieke registratienummers worden verplicht op alle productetiketten.\",\n    \"Online toegang tot volledige ingrediëntenlijsten, allergenen en waarschuwingen.\",\n    \"Producten zonder registratie worden als illegaal beschouwd en uit de handel genomen.\"\n  ],\n  \"pt_ai_title\": \"Lei de Listagem de Suplementos Dietéticos de 2026\",\n  \"pt_summary\": \"Esta lei exige que os fabricantes registem os seus suplementos na FDA para aumentar a transparência. Será criada uma base de dados pública onde os cidadãos podem verificar ingredientes e avisos de segurança dos produtos.\",\n  \"pt_key_points\": [\n    \"Registo obrigatório de todos os suplementos dietéticos comercializados na FDA.\",\n    \"Criação de uma base de dados eletrónica pública para consulta dos consumidores.\",\n    \"Exigência de um número de identificação oficial nos rótulos dos suplementos.\",\n    \"Disponibilização online de listas de ingredientes, alergénios e avisos de segurança.\",\n    \"Produtos não registados serão considerados irregulares e retirados do mercado.\"\n  ],\n  \"category\": [\"Health\", \"Economy\"]\n}"
    }
  ]
}